جست‌وجوی استاد و پژوهشگر

• Drug Delivery
• Nanomedicine
• Biopharmaceutics
• +۷ مورد دیگر

Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.

Jacques Archambaultمشاهده پروفایل

استاد

• Human Papillomavirus (HPV)
• Polyomavirus
• Viral DNA Replication
• +۴ مورد دیگر

Dr. Jacques Archambault is a Professor in the Department of Microbiology and Immunology at McGill University , and an associate member of the Division of Experimental Medicine since 2016. His research focuses on the molecular biology and pathogenesis of human papillomaviruses (HPVs) and polyomaviruses (HPyVs), with an emphasis on their replication mechanisms as episomes in host cells. The Archambault laboratory employs functional genomics, proteomics, and chemical biology approaches to identify cellular pathways exploited by these viruses and develop high-throughput assays for screening small molecule inhibitors of viral replication. Analysis of his recent publications reveals a strong focus on HPV and HPyV replication machinery, including studies on the E1 helicase, UAF1-USP1 interactions, and structural characterization of viral proteins involved in DNA replication. His work bridges virology, oncology, and drug discovery, particularly targeting oncogenic HPV types implicated in anogenital and oropharyngeal cancers, as well as HPyVs like BKPyV and JCPyV that cause pathologies in immunosuppressed patients. Current efforts in the lab aim to elucidate the molecular mechanisms by which HPVs and HPyVs replicate their genomes and to develop antiviral therapies targeting these processes. Techniques such as fluorescence anisotropy, NMR spectroscopy, and crystallography are frequently employed to study protein-DNA and protein-protein interactions critical to viral replication.

Nika Danialمشاهده پروفایل

دانشیار

• Metabolic Biology
• Cancer Research
• Diabetes
• +۴ مورد دیگر

Dr. Nika Danial is an Associate Professor of Cell Biology at Harvard Medical School and the Department of Cancer Biology at Dana-Farber Cancer Institute. She leads the Danial Lab, investigating metabolic mechanisms that regulate cellular adaptation to stress, with a focus on fuel utilization in health and disease. Dr. Danial holds additional roles as Co-Director of the NCI-funded T32 Training Program in Cancer Chemical Biology and Metabolism. Her research integrates biochemistry, mouse models, and metabolomics to study metabolic contributions to cancer, diabetes, and neurological disorders. Education: PhD from Columbia University (1999), postdoctoral training at Harvard Medical School and Dana-Farber under Dr. Stanley Korsmeyer. Key research areas include mitochondrial dynamics, glucose metabolism pathways, and the interplay between inflammation and metabolic signaling. The lab has pioneered studies on how metabolic flexibility impacts disease progression in pancreatic islets, lymphoma subtypes, and neuronal excitability. Publications highlight discoveries in mitochondrial fatty acid oxidation regulation, urea cycle anti-inflammatory mechanisms, and metabolic signatures in cancer subtypes. Her work has implications for developing therapies targeting metabolic vulnerabilities in diseases like diffuse large B-cell lymphoma and type 1 diabetes. The Danial Lab emphasizes rigorous training for the next generation of scientists through mentorship programs and interdisciplinary collaboration.

• Environmental Toxicology
• Reproductive Health
• Metabolic Disorders
• +۳ مورد دیگر

Dr. Alison Holloway is a Professor at McMaster University's Faculty of Health Sciences, specializing in environmental toxicology and reproductive health. Her research focuses on the effects of environmental contaminants (e.g., oil sands pollutants, pesticides, endocrine disruptors) on maternal and child health, metabolic disorders, and developmental outcomes. She has conducted studies on naphthenic acids, synthetic food additives, and maternal exposure to pharmaceuticals like fluoxetine. Key research areas include: Environmental contaminants' impact on reproductive systems and placental function Metabolic disturbances caused by chemical exposures during critical developmental windows Neurobehavioral and gastrointestinal effects of prenatal drug exposure Assessment of urban air pollution on in vitro fertilization (IVF) success rates Her recent work highlights the role of the tryptophan-kynurenine pathway as a biomarker of environmental stress and the obesogenic effects of bisphenol analogs and food additives. Collaborations involve interdisciplinary teams addressing environmental health, with studies published in high-impact toxicology and public health journals. Dr. Holloway's research has informed policies on chemical safety and maternal health, emphasizing cross-species markers for organismal health and risk assessment of emerging contaminants like cannabis derivatives.

• Immunology
• Lipid Metabolism
• Infectious Diseases
• +۳ مورد دیگر

Dijin Xu is an Associate Research Scientist in the Department of Microbial Pathogenesis at Yale School of Medicine, Yale University. His research focuses on lipid metabolism, immunology, and molecular mechanisms underlying metabolic disorders and host-pathogen interactions. He holds a PhD from Tsinghua University (2016). Education: PhD in Microbiology, Tsinghua University, 2016 Research Interests: Dr. Xu’s work spans immunology (e.g., B cell biology and somatic hypermutation), lipid metabolism (lipid droplet dynamics and adipose tissue homeostasis), and virology (antiviral defense mechanisms against SARS-CoV-2). His studies integrate cellular biology, molecular genetics, and biochemical approaches to understand disease processes. Publications Overview: His recent work explores mechanisms of lipid droplet regulation, metabolic disorder prevention, and immune system function. Notable contributions include studies on Rab GTPases in lipid storage and ELOF1’s role in antibody diversification. Labs & Affiliations: He is affiliated with the West Campus Integrative Science & Technology Center at Yale University, focusing on interdisciplinary research in cellular and molecular biology.

• Redox Biology
• Cancer Research
• Drug Metabolism
• +۴ مورد دیگر

Zhiwei Ye is an Associate Professor in the Department of Pharmacology & Immunology at the College of Medicine, Medical University of South Carolina. His research focuses on redox biology, cancer mechanisms, and drug metabolism with a particular emphasis on mitochondrial function, oxidative stress, and therapeutic resistance. He holds a PhD in Pharmaceutical Science from Katholieke Universiteit Leuven (Belgium, 2009) and prior degrees from Zhejiang University (China). PhD in Pharmaceutical Science, 2009 – Katholieke Universiteit Leuven, Belgium Master in Pharmaceutical Science, 2005 – Katholieke Universiteit Leuven, Belgium Master in Medicine, 2003 – Zhejiang University, China B.S. in Pharmacy, 2000 – Zhejiang University, China Dr. Ye’s research explores how redox regulation impacts cancer progression, drug resistance, and metabolic disorders. His work integrates enzymology (e.g., GSTP, PDI), mitochondrial dynamics, and zebrafish models to study mechanisms like S-glutathionylation, VDAC targeting, and drug-transporter interactions. Recent studies highlight novel therapeutic strategies for hepatocellular carcinoma, melanoma, and myeloma through modulation of redox pathways. Publications emphasize translational research bridging basic biology and clinical applications, including drug development (e.g., Telintra) and understanding treatment resistance in malignancies. His work also addresses metabolic disease mechanisms, such as hepatic steatosis and drug-induced renal toxicity. No scientific awards explicitly mentioned in provided texts. Active in grant-funded research areas like cancer biology and redox signaling. Collaborates on projects involving drug-transporter profiling in hepatocytes and cellular stress responses.

• Pediatric Critical Care Medicine
• Developmental Biology
• Organogenesis
• +۷ مورد دیگر

Clifford W. Bogue, MD , is the Waldemar Von Zedtwitz Professor of Pediatrics, Chair of the Department of Pediatrics at Yale School of Medicine, and Chief of Pediatrics for the Yale New Haven Health System. He has been a faculty member at Yale since 1993 and has held numerous leadership roles, including Interim Chairman of Pediatrics, Chief Medical Officer of Yale-New Haven Children’s Hospital, and Director of Pediatric Critical Care programs. Education: BA and MD from the University of Virginia; Residency and Chief Residency at Vanderbilt University; Fellowship in Pediatric Critical Care at Yale. Dr. Bogue is a pediatric critical care specialist whose research centers on the molecular mechanisms of organ development, particularly the role of the Hhex gene in liver, cardiovascular, and lung organogenesis. His lab used mouse models to uncover critical genetic pathways in embryonic development, with implications for regenerative medicine. His recent work also extends into pediatric public health, critical care infrastructure, and health equity. An analysis of his recent publications reveals a sustained focus on developmental genetics, with increasing engagement in clinical and policy-oriented research in pediatrics. His work spans molecular biology, translational models, and national health initiatives, reflecting a broad scholarly impact. His scientific honors include: President of the American Pediatric Society (2024–2025) Norman J. Siegel Faculty Award Marna P. Borgstrom Lifetime Achievement Award Consistent recognition in Best Doctors in America since 2004 Honorary M.A. from Yale University Dr. Bogue has been deeply involved in training the next generation of physician-scientists, serving as PI of an NIH T32 program, Training Director of the Yale Child Health Research Center (K12), and mentor in the MD/PhD program. He has contributed to national pediatric research policy through roles in the American Academy of Pediatrics, NIH advisory committees, and the Charles H. Hood Foundation. He leads or has led significant research initiatives, including an NIH-funded program on cardiopulmonary development and the Bedside to Bench seminar for medical students. His leadership extends to national boards and editorial roles, including Section Editor for Current Opinion in Pediatrics .

Ype P. de Jongمشاهده پروفایل

استادیار

• Viral Hepatitis
• Hepatology
• Liver Disease
• +۷ مورد دیگر

Dr. Ype P. de Jong is an Assistant Professor of Medicine at Weill Cornell Medical College of Cornell University and an Attending Physician at New York-Presbyterian Hospital. He completed his medical and doctoral training at the University of Amsterdam, followed by internal medicine and gastroenterology fellowships at Mount Sinai Hospital, New York. His research focuses on hepatitis virus immune evasion, liver disease modeling, and gene therapy applications. Education M.D., University of Amsterdam Faculty of Medicine (2003) Ph.D., University of Amsterdam (2002) Research Interests Dr. de Jong investigates hepatitis virus persistence mechanisms, develops advanced liver disease models, and explores gene therapy applications for hemophilia and liver conditions. His work bridges clinical hepatology with translational research on viral immune evasion and hepatocyte engineering. Scientific Awards Cum Laude (PhD thesis), University of Amsterdam (2002) Hippocrates Prize (Best Medical Thesis in Netherlands), Leiden University (2003) Appointments Assistant Professor of Medicine, Weill Cornell Medical College Attending Physician, New York-Presbyterian Hospital Visiting Clinical Fellow, The Rockefeller University

• Virology
• Vaccine Development
• Hepatitis Viruses
• +۵ مورد دیگر

Lars Frelin is an Associate Professor in Virology at Karolinska Institutet, where he also serves as Programme Director for the Study Programme in Biomedical Laboratory Science and the Master Programme in Diagnostic Cytology. He is the Facility Manager for ANA Futura and a member of the VIVAC (Vaccines and Immunotherapies against Viruses And Cancer) research group led by Matti Sällberg at the Department of Laboratory Medicine, Division of Clinical Microbiology. Dr. Frelin's academic background includes: PhD from Karolinska Institutet (2004) Docent (Associate Professor) in Virology, Karolinska Institutet (2013) His research focuses on vaccine development against infectious diseases, particularly hepatitis viruses. Working with the VIVAC research group, he investigates novel immunotherapeutic approaches to combat viral hepatitis B, C, and D. His work spans from basic virology to translational research, with an emphasis on understanding viral immune evasion strategies and developing therapeutic vaccines that can overcome immune tolerance in chronic infections. Dr. Frelin's scientific contributions span over two decades, with recent work focusing on universal coronavirus vaccines, novel prime-boost strategies for hepatitis viruses, and understanding the immune response to viral infections. His research demonstrates a consistent trajectory toward developing immunotherapies that target viral entry mechanisms and enhance host immune responses against persistent viral infections. Dr. Frelin has secured multiple research grants from the Swedish Research Council, including: "Pathogenesis and immune evasion strategies of hepatitis viruses: New transgenic mouse models and new therapies" (2020-2022) "Pathogenesis and immune evasion strategies of hepatitis viruses: New transgenic mouse models and new therapies" (2017-2019) "Understanding the hepatitis C virus nonstructural 5A protein: A new target for antiviral therapies" (2012-2014) As Programme Director, he oversees academic programs in Biomedical Laboratory Science and Diagnostic Cytology, shaping the education of future laboratory medicine professionals. His leadership extends to serving on the Infrastructure Committee at Karolinska Institutet (2016-2019, 2019-2022) and managing the ANA Futura facility since 2020. Dr. Frelin is an active member of the VIVAC research group, which focuses on developing vaccines and immunotherapies against viruses and cancer. The group employs various approaches including DNA vaccine technology, viral vector systems, and novel delivery methods to enhance immune responses against challenging viral targets.

Linda Kockمشاهده پروفایل

استادیار

• Biomechanics
• Tissue Engineering
• Orthopaedics
• +۴ مورد دیگر

Linda Kock is an Assistant Professor (Part-time) in the Department of Biomedical Engineering at Eindhoven University of Technology, specializing in the Orthopaedic Biomechanics research group. Her work focuses on developing ex vivo models for studying bone dynamics, liver function, and tissue engineering applications. Dr. Kock's research primarily centers on biomechanics and tissue engineering, with particular emphasis on: Ex vivo culture systems for bone and cartilage tissue Liver perfusion and transplantation models Organoid development and application in regenerative medicine Longitudinal monitoring of tissue dynamics using advanced imaging techniques Development of alternatives to animal experimentation in medical research Her recent publications demonstrate a strong focus on creating clinically relevant ex vivo models that bridge the gap between laboratory research and clinical applications, particularly in orthopaedics and liver transplantation. She has developed innovative approaches for monitoring bone remodeling through micro-CT scanning and has investigated the use of slaughterhouse-obtained livers as alternatives to laboratory pigs for perfusion research. Dr. Kock has received research funding from several prestigious sources including the European Union's Horizon 2020 research program under Marie Sklodowska-Curie grant agreements and the Netherlands Organization for Scientific Research through the ERC Proof of Concept program and Gravitation Program. She is actively contributing to the advancement of regenerative medicine techniques that align with the 3Rs principle (Replacement, Reduction, Refinement) in medical research, providing valuable platforms for testing drug treatments and evaluating implant performance under controlled conditions that better reflect human physiology.

Dajana Vuckovicمشاهده پروفایل

استاد

• analytical chemistry
• metabolomics
• lipidomics
• +۷ مورد دیگر

Dajana Vuckovic, PhD, is a full Professor and Concordia University Research Chair in the Department of Chemistry and Biochemistry at Concordia University's School of Health. She directs the Centre for Biological Applications of Mass Spectrometry (CBAMS) and leads an active research group. Her education includes a PhD from the University of Waterloo and an NSERC Postdoctoral Fellowship at the University of Toronto. Dr. Vuckovic's research focuses on cutting-edge analytical chemistry methodologies with emphasis on: Advanced mass spectrometry techniques for metabolomics and lipidomics Innovative sample preparation approaches for complex biological matrices Biomarker discovery and validation for cardiovascular health and inflammation Development of standardized protocols for untargeted analysis Applications in nutrition and neurological research Her extensive publication record demonstrates a consistent focus on analytical method development, particularly in LC-MS based metabolomics and lipidomics. Recent works emphasize QA/QC standardization, tissue analysis advancements, and novel applications in neuroscience and cardiovascular research. Awards & Honors: PetroCanada Young Innovator Award As Director of CBAMS, she oversees interdisciplinary research in biological mass spectrometry. She actively contributes to professional organizations including the Metabolomics Association of North America (Board Member), Metabolomics Innovation Centre, and Metabolomics Quality Assurance and Quality Control Consortium (mQACC).

Juliette Leglerمشاهده پروفایل

استاد

• Toxicology
• Endocrinology
• Developmental Biology
• +۳ مورد دیگر

Prof. Juliette Legler is a Professor of Toxicology at Utrecht University's Institute for Risk Assessment Sciences (IRAS), within the Faculty of Veterinary Medicine. She leads the Division of Toxicology and previously headed the Department of Population Health Sciences (2020–2022). Her research focuses on environmental contaminants' molecular mechanisms, particularly endocrine-disrupting chemicals (EDCs), microplastics, and metabolic disorders. She coordinates major EU projects like GOLIATH (testing metabolism disruptors) and the Microplastics and Human Health Consortium (MOMENTUM), investigating fetal exposure risks. She also leads the Virtual Human Platform for Safety Assessment (VHP4Safety), advancing animal-free testing methods. Education and Career: Before Utrecht, she held roles at Brunel University London (2018) and Vrije Universiteit Amsterdam (2001–2015), where she became a Professor of Toxicology in 2013. She is a European Registered Toxicologist and former President of the Netherlands Society of Toxicology (2019–2022). Research Interests: Her work spans EDC impacts on human and wildlife health, microplastic exposure in fetal environments, and developing in vitro models to replace animal testing. Key projects include the EURION and ENKORE clusters for EDC research and the AFARA project for regulatory acceptance of non-animal assays. Publications and Awards: Over 100 publications, including landmark studies on microplastics and EDCs. Awards include the Poulsson Prize (2018), EUROTOX Lecture Award (2024), and ZonMw Pearl Award for microplastics research. She also received the VENI and VIDI grants from NWO. Grants and Projects: Coordinates €11.4M NWO projects (VHP4Safety, AFARA) and European H2020 initiatives (GOLIATH, AURORA). Her work bridges academia, industry, and policy to address environmental health challenges. Labs/Teams: Active in IRAS, leading cross-disciplinary teams in toxicology, in vitro modeling, and environmental health. Collaborates with global networks like the EURION and AURORA consortia.

Kenneth Sumidaمشاهده پروفایل

استاد

• Resistance Training
• Caloric Restriction
• Bone Mineral Density
• +۳ مورد دیگر

Dr. Kenneth Sumida is a Professor at Chapman University holding the Warren D. Hancock Endowed Chair in Natural Sciences. He is affiliated with both Crean College of Health and Behavioral Sciences and Schmid College of Science and Technology, conducting research at the intersection of exercise physiology and musculoskeletal biology. University of Southern California - BS, MS, PhD Research Focus : Dr. Sumida investigates exercise-induced bone formation thresholds during growth periods, particularly examining sex differences in bone mineral density (BMD) responses to resistance training. His work also explores alcohol's impact on hepatic glucose production , revealing sex-specific metabolic vulnerabilities. Publication Trends : Recent work spans 2025-2007, showing a progression from alcohol metabolism studies to groundbreaking work on optimal resistance training protocols for skeletal development. Key themes include nonlinear BMD responses , training frequency equivalence , and caloric restriction interactions . Awards & Memberships : Fellow of the American College of Sports Medicine Member of the American Physiological Society Teaching & Funding : He teaches advanced physiology courses (PT 515, BIOL 365/366, BIOL 350) while securing grants from NIH National Institute on Alcohol Abuse & Addiction, NIH National Institute on Aging, and Irvine Health Foundation.

Carl Richardsمشاهده پروفایل

استاد

• Immunology
• Cytokine Biology
• Inflammation
• +۴ مورد دیگر

Carl Richards is a Professor of Medicine at McMaster University and serves as Director of the McMaster Immunology Research Centre (MIRC) since 2014. He is one of 14 faculty members within MIRC, housed in state-of-the-art research facilities at the Michael DeGroote Centre for Learning and Discovery (MDCL). Dr. Richards earned his MSc (1984) and PhD (1987) in Medical Sciences from McMaster University, followed by postdoctoral training at Cambridge University as a Canadian Arthritis Society Scholar (1988-1990). He served two terms (2001-2009) as Associate Dean of Graduate Studies (Health Sciences), developing the MD/PhD program and BioMedical Engineering graduate programs. He was a member of McMaster Senate (2010-2016) and chaired the Senate Committee on Appointments (2013-15). His research focuses on immunology with special emphasis on cytokine biology, particularly Oncostatin M. His work spans inflammation, bone remodeling, pulmonary immunology, and macrophage biology. Analysis of his recent publications reveals consistent focus on Oncostatin M's role in inflammatory pathways, lung fibrosis, macrophage polarization, and cytokine networks, with increasing emphasis on molecular mechanisms and therapeutic targeting. Dr. Richards has served on national peer-reviewed granting agencies including CIHR operating grant panels as Scientific Officer, and as a grant panel member for the Heart and Stroke Foundation and the Arthritic Society, where he chairs the Strategic Operating Grant Panel. He is an active member of the Canadian Society of Immunology, International Cytokine Society, and Canadian Connective Tissue Society (where he served as President and is currently Past-President). He continues to instruct undergraduate and graduate courses in immunology, including Advanced Immunobiology, Discover Immunology Today, and Inquiry II: Cell Biology, demonstrating his ongoing commitment to education alongside his research activities.

Matt Vijayanمشاهده پروفایل

استاد

• Stress Physiology
• Environmental Toxicology
• Endocrine Regulation
• +۳ مورد دیگر

Matt Vijayan is a Professor in the Department of Biological Sciences at the University of Calgary, holding the NSERC Canada Research Chair (CRC I) in Environmental Physiology and Toxicology, and serving as Associate Head (Research). His research focuses on cellular and molecular mechanisms of stress tolerance, particularly corticosteroid regulation and environmental toxicant impacts on fish physiology. Education: B.F.Sc. (Fisheries Science, Tamil Nadu Agricultural University, 1982), M.F.Sc. (Fish Production, University of Agricultural Sciences, India, 1984), Ph.D. (Animal Physiology, University of Guelph, 1990), and postdoctoral studies at the University of Ottawa (1993). Research interests include stress signaling pathways, endocrine disruption by contaminants, and developmental programming. Current projects explore maternal stress effects, exosome-mediated intercellular communication, and long-term impacts of pollutants like bisphenol A and venlafaxine on fish growth and behavior. His work employs genomic/proteomic approaches, CRISPR-Cas9 knockout models in zebrafish, and field studies with Alberta native fish species. He teaches courses on energy flow in biological systems and animal physiology. Key contributions include identifying non-genomic cortisol signaling mechanisms, characterizing stress axis gene knockouts, and developing behavioral biosensors for environmental contaminants.